Dr Claire Seedhouse is an Associate Professor within the Division of Cancer and Stem Cells, in the School of Medicine, at the University of Nottingham
Claire studied for a BSc (Hons) at Bath University which included two industrial placements (1995). She did her PhD at the Paterson Institute for Cancer Research, Manchester where she developed an interest in DNA damage and repair (1999). After completing several post-doctoral research positions and a fellowship at the University of Nottingham she was appointed as the Skillington Haematology Lecturer in 2009. She has published more than 40 papers (h index 22) and receives external, and local, peer-reviewed funding for her research.
Course Director MSc Oncology
Theme lead for MSc in Clinical Sciences (Blood Sciences)
Claire's area of research is mechanisms of drug resistance in acute myeloid leukaemia (AML), with a particular focus on the DNA damage and repair response. Her work has demonstrated that aberrant DNA… read more
SEEDHOUSE, C.H, HUNTER, H.M., LLOYD-LEWIS, B., MASSIP, A-M., PALLIS, M., CARTER, G.I., GRUNDY, M., SHANG, S. and RUSSELL, N.H., 2006. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412 Leukemia. 20(12), 2130-2136 SEEDHOUSE, C., GRUNDY, M., SHANG, S., RONAN, J., PIMBLETT, H., RUSSELL, N. and PALLIS, M., 2009. Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine Clinical Cancer Research. 15(23), 7291-7298 SEEDHOUSE,, GRUNDY,, WHITE,, LI,, FISHER,, YAKUNINA,, MOORMAN,, HOY,, RUSSELL,, BURNETT, and PALLIS,, 2007. Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials. Clinical Cancer Research. 13(23), 7059-7066
JAWAD, M., SEEDHOUSE, C., MONY, U., GRUNDY, M., RUSSELL, N.H. and PALLIS, M., 2010. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia Leukemia. 24(1), 74-80
Claire's area of research is mechanisms of drug resistance in acute myeloid leukaemia (AML), with a particular focus on the DNA damage and repair response. Her work has demonstrated that aberrant DNA repair pathways may contribute to both the pathogenesis of AML and the resistance of leukaemia cells to genotoxic therapies. Work is now focused upon the differences in the responses to drugs between the distinct subgroups of AML, inclduing those subgroups with FLT3 and/or NPM mutations.
Current research projects include:
- Differences in DNA repair capacities between AML subgroups
- Differences in Bcl2 family members between AML subgroups
- DNA damage and response of AML cells to novel therapeutic drugs, including telomere-targeting agents
- DNA repair in dormant leukaemia cells
- The contribution of single nucleotide polymorphisms to AML pathogenesis and drug resistance